Developer docs
API playgroundTry for free, no card

Search company profiles

Neogenix Biosciences

Full company profile

uuid000hojf

Namestring
Neogenix Biosciences
Legal namestring
NeoGenix Biosciences Pty Ltd
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IVF medical devices, sperm selection technology, AI sperm detection, microfluidic fertility devices, assisted reproductive technology
Industry3 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAKAJAC
Reproductive Endocrinology & Infertility (IVF/Fertility)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Fertility Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SpermSearch.AI Software
TypeSubscription Recurring
Description

AI-powered software platform sold as a co-pilot tool for embryologists in IVF laboratories. Currently offered through Early Access Program for evaluation.

neogenixbiosciences.com
2SpermGuide Device
TypeHardware Sales
Description

Microfluidic sperm selection device in development. To be commercialized as a medical device for laboratory use in sperm isolation procedures.

neogenixbiosciences.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Early Access Program for SpermSearch.AI
ModelOtherBilling cadenceMulti-year contract
Notes

Research Use Only conditions with feedback collection for product development

neogenixbiosciences.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1SpermGuide
Description

A microfluidic, channel-based device that passively selects highly-motile sperm with low DNA fragmentation using biomimetic geometries without centrifugation.

neogenixbiosciences.com
+1 more record
Core offering1 text field

Neogenix Biosciences develops and commercializes AI and microfluidic technologies for sperm identification and selection in IVF laboratories. The company's core offerings are SpermSearch.AI, an AI-powered computer vision software co-pilot that identifies sperm forms in real-time during surgical and extended semen searches, and SpermGuide, a microfluidic device that passively isolates highly-motile sperm with low DNA fragmentation using biomimetic channel geometries. Both products target enterprise IVF clinics globally and are validated through peer-reviewed clinical studies and partnerships with leading fertility centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Significantly better at lowering DNA fragmentation index (DFI) than density gradient centrifugation (DGC) in both research (P = 0.012) and clinical cohorts (P < 0.001)
+4 more records
Product overview1 text field

Neogenix Biosciences is an Australian med-tech company developing a portfolio of two complementary AI and microfluidic technologies for sperm identification and selection in IVF. The core offerings are SpermSearch.AI, an AI-powered computer vision co-pilot that identifies and localizes sperm forms in real-time during surgical and semen extended sperm searches, and SpermGuide, a microfluidic sperm selection device that passively isolates motile sperm with low DNA fragmentation through biomimetic channel geometries. Together, these technologies address the key bottlenecks in IVF fertility care: accelerating sperm detection in severe male-factor cases and improving sperm quality for fertilization.

Product and service1 record
1SpermSearch.AI
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaborator on the company website, indicating research or development partnership in the reproductive medicine space.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaborator indicating academic research partnership in microfluidics and medical technology development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaborator with research expertise in microfluidics and reproductive technology development. Multiple co-authors from UNSW on published papers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical partner contributing real-world data to NeoGenix. Presented clinical results at ESHRE 2025 including pregnancies and a live birth enabled by SpermSearch.AI. Active collaboration for clinical validation studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian IVF medical-device company (subsidiary of Genea) developing lab instruments and consumables for ART clinics, including sperm preparation and embryo culture systems. Most direct geographic and product overlap with NeoGenix's SpermGuide microfluidic and SpermSearch.AI workflows.

2Memphasys
TypeDirect peer
Description

Australian-listed medtech developing the Felix device, a non-centrifugation sperm separation technology for IVF/ICSI. Directly comparable to SpermGuide in target use case (DNA-fragmentation reduction and operator-bias-free sperm selection).

TypeBroad incumbent
Description

Global Swedish-listed IVF consumables and device company (media, microtools, lab equipment) serving the same IVF clinic buyers. Broad incumbent with the installed base and regulatory reach to bundle or compete with NeoGenix's offerings.

TypeDirect peer
Description

Public company (TSX:HTL) selling laser systems, sperm analyzers (CASA), and lab instruments to IVF and animal-breeding markets. Directly comparable in the IVF lab equipment category and a likely competitor for capital and clinic relationships.

5Fairtility
TypeEmerging player
Description

Israeli AI-in-ART company offering CHLOE, an AI embryo-selection platform for IVF labs. Comparable as an AI co-pilot for embryologists in the same clinical workflow, though focused on embryo rather than sperm morphology.

6Mojo Fertility
TypeEmerging player
Description

European AI-in-IVF startup applying computer vision and machine learning to sperm and embryo analysis. Comparable as a peer-stage AI company competing for the same IVF lab computer-vision category.

TypeEmerging player
Description

French AI-in-ART company offering an IVF decision-support platform that analyzes time-lapse embryo data. Comparable as an early-stage AI co-pilot targeting IVF lab decision workflows.

TypeBroad incumbent
Description

Large US-based women's health and fertility medical-device company with a broad portfolio including IVF media, microtools, and lab equipment. Comparable as a broad incumbent with established IVF clinic relationships NeoGenix must sell into.

TypeBroad incumbent
Description

Major ART media, equipment, and device supplier acquired by Fujifilm. Comparable as a broad incumbent supplying IVF labs with the consumables and instruments that sit alongside NeoGenix's sperm-selection workflow.

10Carl Zeiss Microscopy
TypeOthers
Description

Microscope manufacturer whose imaging platforms underpin IVF lab workflows and with whom NeoGenix already collaborates via Evident. Relevant as an ecosystem partner/incumbent that could integrate competing AI detection features into its hardware.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neogenix Biosciences

Fertility Medical Devicesneogenixbiosciences.com

Neogenix Biosciences firmographics

Firmographics
Name
Neogenix Biosciences
Legal name
NeoGenix Biosciences Pty Ltd
Website
https://neogenixbiosciences.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Neogenix Biosciences industry classification

Industry
Product category
Fertility Medical Devices
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAKAJAC
Reproductive Endocrinology & Infertility (IVF/Fertility)

Keywords

  • IVF medical devices
  • Sperm selection technology
  • AI sperm detection
  • Microfluidic fertility devices
  • Assisted reproductive technology

Where Neogenix Biosciences is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Neogenix Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. SpermSearch.AI Software: AI-powered software platform sold as a co-pilot tool for embryologists in IVF laboratories. Currently offered through Early Access Program for evaluation.
  2. SpermGuide Device: Microfluidic sperm selection device in development. To be commercialized as a medical device for laboratory use in sperm isolation procedures.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEarly Access Program for SpermSearch.AI

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Neogenix Biosciences product offering

Product offering

Core offering

Neogenix Biosciences develops and commercializes AI and microfluidic technologies for sperm identification and selection in IVF laboratories. The company's core offerings are SpermSearch.AI, an AI-powered computer vision software co-pilot that identifies sperm forms in real-time during surgical and extended semen searches, and SpermGuide, a microfluidic device that passively isolates highly-motile sperm with low DNA fragmentation using biomimetic channel geometries. Both products target enterprise IVF clinics globally and are validated through peer-reviewed clinical studies and partnerships with leading fertility centers.

Product overview

Neogenix Biosciences is an Australian med-tech company developing a portfolio of two complementary AI and microfluidic technologies for sperm identification and selection in IVF. The core offerings are SpermSearch.AI, an AI-powered computer vision co-pilot that identifies and localizes sperm forms in real-time during surgical and semen extended sperm searches, and SpermGuide, a microfluidic sperm selection device that passively isolates motile sperm with low DNA fragmentation through biomimetic channel geometries. Together, these technologies address the key bottlenecks in IVF fertility care: accelerating sperm detection in severe male-factor cases and improving sperm quality for fertilization.

Differentiator

Problem solved

Functional benefit

Brands

  • SpermGuide: A microfluidic, channel-based device that passively selects highly-motile sperm with low DNA fragmentation using biomimetic geometries without centrifugation.
  • SpermSearch.AI

Products and services

  • SpermSearch.AI

Quantifiable outcome

  • Significantly better at lowering DNA fragmentation index (DFI) than density gradient centrifugation (DGC) in both research (P = 0.012) and clinical cohorts (P < 0.001)
  • +4 more outcomes

Companies that use Neogenix Biosciences

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Neogenix Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Neogenix Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • AMA (Australian Medical Association)minorStrategic or Co-development PartnerListed as a collaborator on the company website, indicating research or development partnership in the reproductive medicine space.
  • University of Technology Sydney (UTS)minorStrategic or Co-development PartnerListed as a collaborator indicating academic research partnership in microfluidics and medical technology development.
  • UNSW AustraliaminorStrategic or Co-development PartnerListed as a collaborator with research expertise in microfluidics and reproductive technology development. Multiple co-authors from UNSW on published papers.
  • IVF AustraliacoreStrategic or Co-development PartnerClinical partner contributing real-world data to NeoGenix. Presented clinical results at ESHRE 2025 including pregnancies and a live birth enabled by SpermSearch.AI. Active collaboration for clinical validation studies.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Neogenix Biosciences competitors and assessment

Company assessment

Direct peers

  • Genea Biomedx: Australian IVF medical-device company (subsidiary of Genea) developing lab instruments and consumables for ART clinics, including sperm preparation and embryo culture systems. Most direct geographic and product overlap with NeoGenix's SpermGuide microfluidic and SpermSearch.AI workflows.
  • Memphasys: Australian-listed medtech developing the Felix device, a non-centrifugation sperm separation technology for IVF/ICSI. Directly comparable to SpermGuide in target use case (DNA-fragmentation reduction and operator-bias-free sperm selection).
  • Hamilton Thorne: Public company (TSX:HTL) selling laser systems, sperm analyzers (CASA), and lab instruments to IVF and animal-breeding markets. Directly comparable in the IVF lab equipment category and a likely competitor for capital and clinic relationships.

Broad incumbents

  • Vitrolife: Global Swedish-listed IVF consumables and device company (media, microtools, lab equipment) serving the same IVF clinic buyers. Broad incumbent with the installed base and regulatory reach to bundle or compete with NeoGenix's offerings.
  • CooperSurgical: Large US-based women's health and fertility medical-device company with a broad portfolio including IVF media, microtools, and lab equipment. Comparable as a broad incumbent with established IVF clinic relationships NeoGenix must sell into.
  • FUJIFILM Irvine Scientific: Major ART media, equipment, and device supplier acquired by Fujifilm. Comparable as a broad incumbent supplying IVF labs with the consumables and instruments that sit alongside NeoGenix's sperm-selection workflow.

Emerging players

  • Fairtility: Israeli AI-in-ART company offering CHLOE, an AI embryo-selection platform for IVF labs. Comparable as an AI co-pilot for embryologists in the same clinical workflow, though focused on embryo rather than sperm morphology.
  • Mojo Fertility: European AI-in-IVF startup applying computer vision and machine learning to sperm and embryo analysis. Comparable as a peer-stage AI company competing for the same IVF lab computer-vision category.
  • ImVitro: French AI-in-ART company offering an IVF decision-support platform that analyzes time-lapse embryo data. Comparable as an early-stage AI co-pilot targeting IVF lab decision workflows.

Others

  • Carl Zeiss Microscopy: Microscope manufacturer whose imaging platforms underpin IVF lab workflows and with whom NeoGenix already collaborates via Evident. Relevant as an ecosystem partner/incumbent that could integrate competing AI detection features into its hardware.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Neogenix Biosciences social profiles

Digital presence

Neogenix Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neogenix Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Neogenix Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neogenix Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neogenix Biosciences

What does Neogenix Biosciences do?

Neogenix Biosciences develops and commercializes AI and microfluidic technologies for sperm identification and selection in IVF laboratories. The company's core offerings are SpermSearch.AI, an AI-powered computer vision software co-pilot that identifies sperm forms in real-time during surgical and extended semen searches, and SpermGuide, a microfluidic device that passively isolates highly-motile sperm with low DNA fragmentation using biomimetic channel geometries. Both products target enterprise IVF clinics globally and are validated through peer-reviewed clinical studies and partnerships with leading fertility centers.

Is Neogenix Biosciences a public or private company?

Neogenix Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neogenix Biosciences founded?

Neogenix Biosciences was founded in 2019. It employs 1 to 10 people.

Where is Neogenix Biosciences based?

Neogenix Biosciences is headquartered in Sydney, Australia, in the Oceania region.

How does Neogenix Biosciences make money?

Two revenue lines are on record. SpermSearch.AI Software is the primary driver. The others are spermGuide Device.

Who are Neogenix Biosciences's main competitors?

Direct peers on record are Genea Biomedx, Memphasys and Hamilton Thorne. Broad incumbents are Vitrolife, CooperSurgical and FUJIFILM Irvine Scientific. Emerging players are Fairtility, Mojo Fertility and ImVitro. Carl Zeiss Microscopy is listed as an others.

Does Neogenix Biosciences have an API?

No public API is recorded for Neogenix Biosciences.

What industry is Neogenix Biosciences in?

Neogenix Biosciences's product category is Fertility Medical Devices. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales